

Supplemental Online Content

Heudel P, Frenel J-S, Dalban C, et al. Safety and efficacy of the mTOR inhibitor, vistusertib, combined with anastrozole in patients with hormone receptor–positive recurrent or metastatic endometrial cancer: the VICTORIA multicenter, open-label, phase 1/2 randomized clinical trial. *JAMA Oncol*. Published online May 12, 2022. doi:10.1001/jamaoncol.2022.1047


eFigure 1. Schematic Representation of the Randomized Patients According to Treatment Allocation.

eFigure 2. CONSORT with Screen Fail

This supplemental material has been provided by the authors to give readers additional information about their work.


Figure S1. Schematic representation of the randomized patients according to treatment allocation.

VISTUSERTIB+ ANASTROZOLE



Time from randomization (months)

ANASTROZOLE



Time from randomization (months)

CONSORT with screen fail

